3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1/2
3
Phase NA
2
Phase 3
1
Phase 1
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
3
Conditions
Carcinoma, Non-Small-Cell Lung
48
Neoplasms
27
Colorectal Neoplasms
26
Neoplasm Metastasis
24
Recurrence
22
Ovarian Neoplasms
22
Pancreatic Neoplasms
21
Breast Neoplasms
20
Squamous Cell Carcinoma of Head and Neck
18
Prostatic Neoplasms
18
Melanoma
17
Glioblastoma
15
Lymphoma, Large B-Cell, Diffuse
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma, Non-Hodgkin
13
Endometrial Neoplasms
13
Multiple Myeloma
12
Lung Neoplasms
12
Colonic Neoplasms
12
Triple Negative Breast Neoplasms
11
Carcinoma, Renal Cell
11
Stomach Neoplasms
10
Leukemia, Myeloid, Acute
10
Glioma
10
Gastrointestinal Neoplasms
10
Rectal Neoplasms
9
Lymphoma, Follicular
9
Lymphoma
9
Head and Neck Neoplasms
8
Burkitt Lymphoma
8
Interventions
Vincristine
1
Rituximab
1
R-CHOP protocol
1
Prednisone
1
Oxaliplatin
1
Maintenance
1
Lenalidomide
1
Gemcitabine
1
Doxorubicin
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, B-Cell, Marginal Zone
×
30 days
×
Clear all
NCT05006716
2026-06-03
CaDAnCe-101
BeOne Medicines
Phase 1/2
Recruiting
645 enrolled
NCT03625037
2026-06-02
EPCOREâ„¢ NHL-1
Genmab
Phase 1/2
Active not recruiting
666 enrolled
2 FDA
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled